Peginterferon alfa-2a

Drug Profile

Peginterferon alfa-2a

Alternative Names: PEG IFN-α-2a; PEG interferon-α-2a; Pegasys; Pegferon; Pegylated interferon-alpha-2a; R 442; RG 442; RG 964; RO 25-8310; RO 253036

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche; University of Pennsylvania
  • Class Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C
  • Phase III Chronic myeloid leukaemia; Hepatitis D
  • Phase II HIV-1 infections
  • Discontinued Malignant melanoma; Renal cell carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-B in Singapore (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-C(Treatment-experienced) in Germany (IV)
  • 12 Oct 2017 Preregistration for Hepatitis B (In adolescents, In children) in European Union (SC) before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top